CTT-1057

DB14965InvestigationalSmall molecule

CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).

Mechanism: Pharmacologically active on Glutamate carboxypeptidase 2
Curator reviewed
Formula / weight: C₂₈H₄₀FN₄O₁₄P · 706.6078 g/mol (avg)
Code names: CTT-1057

Resolves to

Compound

UNIIQMH3V8VSPBCAS1628717-55-4ChEMBLCHEMBL3427435

Structure

InChIKeyIZLOSIXADNUSCM-ACRUOGEOSA-NSMILESOC(=O)CC[C@H](NP(O)(=O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)C1=CC=C(F)C=C1)C(O)=O)C(O)=O)C(O)=O

Targets

Q04609FOLH1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with CTT-1057, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account